Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Monique C. Minnema, MD PhD, Sanne de Haart, MD, Tuna Mutis, MD PhD, Marco Koudijs, PhD, Marja van Blokland, Henk Lokhorst, MD PhD, Roel de Weger, MD PhD, Stefan Willems, MD PhD

Blood (2015) 126 (23): 4174.

https://doi.org/10.1182/blood.V126.23.4174.4174

Published: 2015

Journal Articles

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Saad Usmani, Brendan Weiss, Nizar J Bahlis, MD, Andrew Belch, Sagar Lonial, MD, Henk Lokhorst, Peter M. Voorhees, MD, Paul G. Richardson, A Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

Blood (2015) 126 (23): 29.

https://doi.org/10.1182/blood.V126.23.29.29

Published: 2015

Journal Articles

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Pieter Sonneveld, Emilie Asselbergs, Sonja Zweegman, Bronno van der Holt, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Annemiek Broyl, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst

Blood (2015) 125 (3): 449–456.

https://doi.org/10.1182/blood-2014-05-576256

Published: 2015

Includes: Supplemental data

Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 4735.

https://doi.org/10.1182/blood.V124.21.4735.4735

Published: 2014

Journal Articles

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Raynier Devillier, MD, Jurjen Versluis, MD, Bronno Van der Holt, PhD, Marie Jose Kersten, MD PhD, Reinier Raymakers, MD PhD, Sonja Zweegman, MD PhD, Gerard M.J. Bos, MDPhD, Nicolaas PM Schaap, Annemiek Broyl, Pieter Sonneveld, MD, Henk Lokhorst, Jan J. Cornelissen, MD PhD

Blood (2014) 124 (21): 1209.

https://doi.org/10.1182/blood.V124.21.1209.1209

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Pieter Sonneveld, MDPhD, Emilie Asselbergs, Bronno Van der Holt, PhD, Sonja Zweegman, MDPhD, Marie jose Kerstens, MD, Edo Vellenga, MD PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2014) 124 (21): 2118.

https://doi.org/10.1182/blood.V124.21.2118.2118

Published: 2014

Journal Articles

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Laurens E. Franssen, MD, Maarten E. Emmelot, BSc, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 2005.

https://doi.org/10.1182/blood.V122.21.2005.2005

Published: 2013

Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1986.

https://doi.org/10.1182/blood.V122.21.1986.1986

Published: 2013

Journal Articles

Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes

Rimke Oostvogels, MD, Rieuwert Hoppes, Henk Lokhorst, Robbert M Spaapen, PhD, Huib Ovaa, PhD, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 5435.

https://doi.org/10.1182/blood.V122.21.5435.5435

Published: 2013

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

Sanne J. de Haart, MD, Monique C. Minnema, MD PhD, Julie H. Huang, PhD, Tineke Aarts-Riemens, Henk Lokhorst, Anton Martens, PhD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 3250.

https://doi.org/10.1182/blood.V122.21.3250.3250

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Pieter Sonneveld, MD, Ph.D, Emilie Asselberg-Hacker, Sonja Zweegman, MD PhD, Bronno van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk Kooy, MD, PhD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst

Blood (2013) 122 (21): 688.

https://doi.org/10.1182/blood.V122.21.688.688

Published: 2013

Journal Articles

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, PhD, Gareth J Morgan, MD PhD, Hartmut Goldschmidt, MD, Uta Bertsch, MD, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3092.

https://doi.org/10.1182/blood.V122.21.3092.3092

Published: 2013

Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 277.

https://doi.org/10.1182/blood.V122.21.277.277

Published: 2013

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

NARROW

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Improved Vaccine Design For Adoptive Immunotherapy In Hematological Malignancies Through Chemically Modified Minor Histocompatibility Antigen Epitopes

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only